AstraZeneca_NNP Annual_JJ Report_NNP and_CC 142_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS 1_CD FIXED_NNP ASSET_NNP INVESTMENTS_NNP Investments_NNP in_IN subsidiaries_NNS Shares_NNP Loans_NNP Total_NNP $_$ m_CD $_$ m_CD $_$ m_CD Cost_NN at_IN beginning_NN of_IN year_NN 6,715_CD 24,197_CD 30,912_CD Additions_NNPS Repayment_NN of_IN loan_NN 6,056_CD 6,056_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2005_CD 6,715_CD 18,141_CD 24,856_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2004_CD 6,715_CD 24,197_CD 30,912_CD 2_CD OTHER_NNP DEBTORS_NNP 2005_CD 2004_CD $_$ m_CD $_$ m_CD Other_JJ debtors_NNS 10_CD Deferred_JJ tax_NN asset_NN 17_CD 25_CD 27_CD 25_CD 3_CD NON-TRADE_JJ CREDITORS_NNS 2004_CD 2005_CD restated_VBN $_$ m_CD $_$ m_CD Amounts_NNS due_JJ within_IN one_CD year_NN Short_JJ term_NN borrowings_NNS unsecured_JJ 5_CD 4_CD Other_JJ creditors_NNS 5_CD 116_CD Amounts_NNS owed_VBN to_TO subsidiaries_NNS 10_CD 2,409_CD 20_CD 2,529_CD 4LOANS_NNP Repayment_NNP 2005_CD 2004_CD dates_NNS $_$ m_CD $_$ m_CD Loans_NNPS owed_VBD to_TO subsidiaries_NNS unsecured_JJ US_NNP dollars_NNS 7.2_CD %_NN loan_NN 2023 283 283_CD Loans_NNPS external_JJ unsecured_JJ US_NNP dollars_NNS 5.4_CD %_NN callable_JJ bond_NN 2014 747 747_CD 1,030_CD 1,030_CD Loans_NNS or_CC instalments_NNS thereof_RB are_VBP repayable_JJ :_: After_IN five_CD years_NNS from_IN balance_NN sheet_NN date_NN 1,030_CD 1,030_CD From_IN two_CD to_TO five_CD years_NNS From_IN one_CD to_TO two_CD years_NNS Total_JJ unsecured_JJ 1,030_CD 1,030_CD Total_JJ due_JJ within_IN one_CD year_NN 1,030_CD 1,030_CD The_DT fair_JJ values_NNS of_IN the_DT external_JJ loans_NNS and_CC the_DT loans_NNS owed_VBN to_TO subsidiaries_NNS are_VBP as_IN follows_VBZ :_: 2005_CD 2004_CD $_$ m_CD $_$ m_CD 7.2_CD %_NN loan_NN 341_CD 338_CD 5.4_CD %_NN callable_JJ bond_NN 770_CD 789_CD 1,111_CD 1,127_CD Both_DT loans_NNS are_VBP at_IN fixed_JJ interest_NN rates_NNS ._.
Accordingly_RB the_DT fair_JJ values_NNS of_IN the_DT loans_NNS will_MD change_VB as_IN market_NN rates_NNS change_VBP ._.
However_RB ,_, since_IN the_DT loans_NNS are_VBP held_VBN at_IN amortised_JJ cost_NN ,_, changes_NNS in_IN interest_NN rates_NNS and_CC the_DT credit_NN rating_NN of_IN the_DT Company_NN will_MD not_RB have_VB an_DT effect_NN on_IN the_DT Companys_NNPS net_JJ assets_NNS ._.
